Pipeline
At Syntara, we leverage our world leading expertise in the field of oxidase enzyme chemistry and biology to inhibit targets responsible for driving extracellular matrix dysfunction. We strive to deliver disease modifying drugs to improve quality of life and extend life expectancy.
| Target | Drug | Indication | Discovery | Pre-Clinical | IND enabling | Phase 1 | Phase 2 | Status |
| Pan LOX | Amsulostat | Myelofibrosis | Trial accrued | |||||
| Myelodysplastic Syndrome | Protocols for two studies under review | |||||||
| Topical Pan-LOX | SNT-9465 | Hypertropic scarring | Protocol under review | |||||
| SNT-6302 | Keloid scarring | Protocol under review | ||||||
| SSAO/ MAO-B | SNT-4728 | IRBD / Parkinson’s Disease | Trial recruiting | |||||
| LOXL2 | SNT-5382 | Organ fibrosis | Clinical safety and target engagement confirmed. | |||||
| MPO / SSAO | SNT-8370 | Inflammation | IND-enabling package complete |
Currently, our clinical development efforts are primarily focused on evaluating novel drugs targeting a subset of oxidase enzymes known as lysyl oxidases. This family of enzymes are uniquely responsible for the development of fibrosis by cross-linking collagen and elastin, resulting in hardened, poorly-degradable scar-like tissue.
Current clinical trials:
Our lead compound, the orally available pan-lysyl oxidase (pan-LOX) inhibitor amsulostat has IND approval, orphan drug designation (US FDA and EMA) and Fast Track designation (FDA).
Amsulostat has completed a Phase 2a trial for myelofibrosis (a blood cancer characterised by bone marrow fibrosis). Two further Phase 1c/2 trials in a second haematological malignancy, myelodysplastic syndrome (MDS), are currently recruiting.
Later this year, in addition to the trials being run in haematological malignancies, amsulostat will be evaluated in combination with standard of care chemotherapy for the treatment of advanced pancreatic cancer.
Syntara’s skin scarring franchise utilises topical pan-LOX inhibitors for the prevention of scar formation and modification of existing scars.
We are currently evaluating SNT-9465 for the treatment of hypertrophic scarring and SNT-6302 for keloid scarring.
Earlier stage opportunities
Earlier stage programs include SNT-5382, a selective lysyl oxidase-like 2 inhibitor developed for the treatment of chronic organ fibrosis, and SNT-8370, a potent inhibitor of two important pro-inflammatory pathways.